Nephros (NASDAQ:NEPH) Releases Quarterly Earnings Results

Nephros (NASDAQ:NEPH) posted its earnings results on Thursday. The company reported $0.06 earnings per share (EPS) for the quarter, Zacks reports. Nephros had a return on equity of 11.03% and a net margin of 8.38%.The firm had revenue of $6.02 million for the quarter, compared to analyst estimates of $4.99 million.

Here are the key takeaways from Nephros’ conference call:

• Record revenue and broad-based growth: Second-quarter revenue reached $6.0 million, up 36% year over year and 15% sequentially. Programmatic product revenue rose 27%, service revenue nearly tripled, and growth was driven largely by increased sales and services within existing customer sites.
• Profitability improved substantially: Net income increased more than 400% to approximately $1.2 million, while adjusted EBITDA rose 260% to $1.3 million. The company ended the quarter with $4.7 million in cash and no debt.
• Reported margins benefited from a one-time tariff refund: The 67% quarterly gross margin included approximately $600,000 of tariff refunds, about $500,000 of which related to inventory sold in prior periods. Management expects tariff policy, currency movements, shipping costs, and the growing mix of lower-margin services and commercial products to continue pressuring underlying margins.
• New products remain an emerging opportunity rather than a current growth driver: PFAS, microplastics, and nanoplastics offerings have not yet gained significant traction and may require additional education, trials, and regulatory momentum. Education initiatives are currently used to drive product adoption and are not being monetized directly.
• Cash generation weakened: Operating cash flow fell to $681,000 in the second quarter from $994,000 a year earlier, while first-half operations used $990,000 as accounts receivable and inventory increased.

Nephros Stock Up 17.3%

Shares of NASDAQ:NEPH traded up $0.62 during trading on Friday, reaching $4.21. The stock had a trading volume of 67,358 shares, compared to its average volume of 10,920. The stock has a market cap of $45.72 million, a P/E ratio of 38.27 and a beta of 1.51. The business has a fifty day moving average price of $3.48 and a 200-day moving average price of $3.53. Nephros has a fifty-two week low of $2.66 and a fifty-two week high of $6.42.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on NEPH. Northland Securities assumed coverage on Nephros in a research report on Friday, July 17th. They set a “market perform” rating and a $4.00 price target for the company. Weiss Ratings upgraded Nephros from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 3rd. Finally, Zacks Research upgraded Nephros to a “hold” rating in a research report on Monday, July 20th. Three research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $4.00.

Institutional Trading of Nephros

Several hedge funds and other institutional investors have recently bought and sold shares of NEPH. Kestra Advisory Services LLC purchased a new position in shares of Nephros during the 4th quarter worth $29,000. Dimensional Fund Advisors LP acquired a new stake in shares of Nephros during the third quarter worth $64,000. Heron Bay Capital Management purchased a new stake in shares of Nephros in the fourth quarter valued at $66,000. Citadel Advisors LLC grew its position in shares of Nephros by 39.2% in the third quarter. Citadel Advisors LLC now owns 16,545 shares of the company’s stock valued at $78,000 after purchasing an additional 4,655 shares during the period. Finally, XTX Topco Ltd increased its stake in Nephros by 48.5% in the fourth quarter. XTX Topco Ltd now owns 21,617 shares of the company’s stock valued at $105,000 after purchasing an additional 7,062 shares during the last quarter. 41.10% of the stock is owned by hedge funds and other institutional investors.

Nephros Company Profile

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.